UMHC acquires MicroThermX Microwave Ablation System

NewsGuard 100/100 Score

BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that the Company has sold a MicroThermX® Microwave Ablation System (MicroThermX®) to the University of Miami Hospital and Clinics (UMHC) to include the Sylvester Comprehensive Cancer Center (Sylvester) and the University of Miami Hospital. The MicroThermX® will be used in both centers.

“We are excited to have state-of-the-art ablation treatment with the MicroThermX® available in these prestigious cancer care facilities”

Sylvester/UMHC serves as the hub for cancer diagnosis and treatment throughout the South Florida area. The UMHC comprehensive network includes three hospitals, more than 30 outpatient facilities, and more than 1,500 physicians and scientists. Sylvester treats more than 4,100 new cancer patients each year, and has transformed cancer research and treatment in South Florida.

"We are excited to have state-of-the-art ablation treatment with the MicroThermX® available in these prestigious cancer care facilities," stated Sam Maravich, BSD's Vice President of Sales and Marketing. "UMHC purchased the MicroThermX® following extensive clinical evaluations. Sylvester previously offered only radiofrequency (RF) ablation, but decided to acquire the MicroThermX® because of its technological advantages. Published studies have demonstrated that microwave ablation has multiple advantages over RF ablation, and the innovative design of the MicroThermX® provides physicians the ability to precisely target the ablation zone to numerous sizes and shapes of tumors."

Source BSD Medical Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
First UK real-world study shows promise for sacituzumab govitecan in metastatic breast cancer